This company has been acquired
MORF Stock Overview
A biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Morphic Holding, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$56.99 |
| 52 Week High | US$57.00 |
| 52 Week Low | US$19.35 |
| Beta | 1.49 |
| 1 Month Change | 1.79% |
| 3 Month Change | 94.97% |
| 1 Year Change | 12.30% |
| 3 Year Change | 1.23% |
| 5 Year Change | 158.58% |
| Change since IPO | 216.61% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
Jun 26
We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 20Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth
Sep 29We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow
Jun 07What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Feb 15We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 03What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Nov 08Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M
Aug 03Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)
May 06Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)
Mar 01Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
Feb 17We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn
Nov 03Morphic: Pioneering Integrin Medicines
Oct 13Shareholder Returns
| MORF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 1.4% | 2.9% |
| 1Y | 12.3% | -14.7% | 11.9% |
Return vs Industry: MORF matched the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: MORF underperformed the US Market which returned 21.7% over the past year.
Price Volatility
| MORF volatility | |
|---|---|
| MORF Average Weekly Movement | 22.6% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: MORF's share price has been volatile over the past 3 months.
Volatility Over Time: MORF's weekly volatility has increased from 15% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 128 | Praveen Tipirneni | www.morphictx.com |
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company’s products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive.
Morphic Holding, Inc. Fundamentals Summary
| MORF fundamental statistics | |
|---|---|
| Market cap | US$2.86b |
| Earnings (TTM) | -US$179.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-15.9x
P/E RatioIs MORF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MORF income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$165.93m |
| Gross Profit | -US$165.93m |
| Other Expenses | US$13.90m |
| Earnings | -US$179.83m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MORF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/15 05:53 |
| End of Day Share Price | 2024/08/15 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Morphic Holding, Inc. is covered by 9 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Goparaju | Berenberg |
| Guyn Kim | BMO Capital Markets Equity Research |
| Julian Harrison | BTIG |